The disclosure of the Q1 2027 earnings summary is expected to exceed 45 days after the quarter end. The delay is due to uncertainties in the accounting treatment of Takara Bio USA, Inc. and delays in audit conclusions. The date for the decision is currently undetermined.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2531","jir_company_name":"Takara Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2531-20260812-01.pdf","jir_short_summary":"The disclosure of the Q1 2027 earnings summary is expected to exceed 45 days after the quarter end. The delay is due to uncertainties in the accounting treatment of Takara Bio USA, Inc. and delays in audit conclusions. The date for the decision is currently undetermined.","jir_summary":"### Background and causes of postponement\nTakara Holdings Co., Ltd. announced that the disclosure of the Q1 2027 earnings summary is expected to exceed 45 days after the quarter end. The direct cause of the postponement is that questions about the accounting treatment of our consolidated subsidiary Takara Bio USA, Inc. were pointed out by the auditors, and further investigation is required to establish factual relationships. We are conducting the investigation with the legal team and accountants, and the timing of the earnings announcement after the postponement is currently undetermined.\n\n### Upcoming schedule and impact\nCurrently, the investigation of facts is continuing with legal professionals and certified public accountants. Once a new decision date is determined, we will promptly disclose it. To avoid confusion for the board of directors and investors, timely information will continue to be provided to relevant parties. Takara Bio USA, Inc.\u2019s overview and the past three years\u2019 sales trends are disclosed as reference information.","jir_financial_highlights":"Sales: Unknown (Unknown)\nDelay in earnings summary disclosure: Unknown (Postponed)","jir_category":"","jir_hashtags":"#TakaraHoldings, #disclosuredelay, #earningssummarydelay","jir_key_figures":"Takara Bio USA, Inc. sales (past 3 years): 2023 Jan-Dec 12,0786 thousand USD, 2024 Jan-Dec 11,3029 thousand USD, 2025 Jan-Dec 10,7217 thousand USD\nDelay in disclosure of quarterly earnings summary: expected to exceed 45 days\nCurrent status of earnings announcement date: undetermined","jir_meta_title":"Takara Holdings Earnings Summary Disclosure Postponement Notice | Q1 2027","jir_meta_description":"Takara Holdings announces that the disclosure of the Q1 2027 earnings summary is expected to exceed 45 days after the quarter end. Investigation into accounting treatment of Takara Bio USA, Inc. is the reason. Further publication dates will be announced as available.","jir_og_title":"Takara Holdings Earnings Summary Postponement Notice","jir_og_description":"Takara Holdings announces postponement of the Q1 earnings summary disclosure. The\u539f\u56e0 is the investigation into accounting treatment of Takara Bio USA, Inc. and delays in audit conclusions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8130,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-102407","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n